During the early stages of development our organisation was fortunate to be deeply involved with immunotherapies (monoclonal antibodies) for haematological cancers and for the treatment of multiple sclerosis.
Through these early experiences we developed valuable insights in the development and operations of studies involving monoclonal antibodies and have successfully leveraged these insights in operationalising studies with immuno-oncology agents.
Our scientific advisory team comprise experts in the highly specialised niche of immunology and immuno-oncology.
They add significant value in defining target populations of patients across tumour types and disease areas.
Copyright @ 2024 Axcellant. Designed By Frantic